Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huashi Baidu Formula vs Molnupiravir in Mild to Moderate COVID-19
NCT05638672Unknown
- Sponsor
- Xiyuan Hospital
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Huashi Baidu Granule in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: Nucleic acid negative rate at 5 days and Virus CT value at 5 days. Status: unknown.
02
Drugs
Huashi Baidu Granule
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05638672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638672.